Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous dose limiting toxicity, today announced the upcoming presentation of the ...

These results validate the importance of EGFR signaling in radiation response ... whether EGFR inhibitors effectively inhibit the key pathways driving EGFR-mediated radioresistance?

We have identified a number of potential downstream targets of Egfr signaling during egg development (via a microarray screen comparing gene expression in ovaries in which the Egfr pathway was up or ...

In a recent study, precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS ...

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and ...

Title: QTX3544, a potent and selective G12V-preferring KRAS inhibitor, synergizes with EGFR inhibitors for enhanced anti-tumor activity Date and Time: Wednesday, April 30, 2025; 9:00 AM - 12:00 PM ...